Close Menu

NEW YORK (GenomeWeb) – PreCyte has received a one-year, $300,000 grant from the National Cancer Institute to develop a blood-based lung cancer diagnostic based on its core Indicator Cell Assay Platform (ICAP) technology.

ICAP was originally developed at the Institute for Systems Biology in the lab of company Co-founder John Aitchison and involves the use of cultured cells as biosensors, exposing them to patient serum and analyzing the transcriptional effect.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.